Navigation Links
Calithera Biosciences Closes $40 Million in Series A Financing
Date:7/8/2010

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million.  Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round.  The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.  

"Promoting apoptosis in cancer cells is a validated approach to the treatment of cancer, as many oncology drugs on the market today are known to kill tumor cells by activating apoptotic pathways, albeit through indirect means," said Susan Molineaux, Ph.D., co-founder and Chief Executive Officer of Calithera.  "By targeting caspases directly, we hope to develop agents that have broad utility across many types of cancer, with greater specificity than current treatments and the potential to overcome chemoresistance."

Calithera's technology was developed by and licensed from the laboratory of co-founder James Wells, Ph.D., chair of the Department of Pharmaceutical Chemistry in the University of California, San Francisco School of Pharmacy.  Dr. Wells's laboratory has successfully identified several novel compounds that selectively activate procaspases and trigger apoptosis in cancer cells.  Proceeds from the financing will be used to advance one or more caspase activators through preclinical development and into Phase 1 clinical trials in cancer patients.  In parallel, the company will ex
'/>"/>

SOURCE Calithera Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. YM BioSciences raises US$3.2 million in support of JAK 1/2 program
7. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
8. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
9. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- New open access, ... serving the international surgical community ... technical, and medical information products and services, today announced ... Surgery Open ( IJS Open ), a ... This peer-reviewed, online-only journal will make significant contributions to ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... On August ... inviting a diverse selection of entrepreneurs from across the United States to talk about ... Richman is honored to be chosen to be among the attendees. , One of ...
(Date:8/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... the second quarter 2015 on Monday, August 10, 2015 ... Torley , president and chief executive officer, will lead ... release financial results for the second quarter 2015. ... "Investors" section of Halozyme,s corporate website and a recording ...
(Date:8/3/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic and Dental sectors of healthcare, announced today that ... Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
Breaking Biology Technology:Elsevier Announces the Launch of International Journal of Surgery Open 2Elsevier Announces the Launch of International Journal of Surgery Open 3Elsevier Announces the Launch of International Journal of Surgery Open 4White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2
... (Nasdaq:,SIAL) announced today the global release of ... researchers to reproducibly,interrogate gene function, via siRNA ... not been considered amenable to conventional lipid-based,siRNA ... reagents exhibit a number,of drawbacks, including high ...
... DIEGO, Oct. 18 Volcano Corporation,(Nasdaq: VOLC ) ... shares of its common stock at a price of ... by Volcano. Volcano has granted the,underwriters a 30-day option ... common stock to cover over-allotments, if any. The offering,is ...
... Oct. 17 AMICAS, Inc. (Nasdaq: AMCS ),a ... today announced it will present to and meet with ... being held in New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... -- Presentation begins promptly at 10:20 a.m. (Eastern ...
Cached Biology Technology:Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2Volcano Corporation Announces Pricing of Common Stock Offering 2
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... elderly people from benefiting equally from exercise, no matter ... published in today's (Aug. 10) Journal of the American ... who exercised stayed healthier than their couch potato peers, ... most from physical activity, said Marco Pahor, M.D., director ...
... a single gene, Nrf2, plays a critical role in ... by Shyam Biswal, PhD, at the Johns Hopkins Bloomberg ... exacerbated allergen-mediated asthma in mice models. The study’s findings, ... Journal of Experimental Medicine, may hold therapeutic potential for ...
... future hopes for human applications , Israeli scientists report ... successfully transplanted whole frozen and thawed ovaries in sheep, ... the laboratory into early embryonic development. , Follow-up tests ... which oocytes were recovered were still functioning normally three ...
Cached Biology News:Exercise aside, genes may ultimately dictate seniors' mobility 2Exercise aside, genes may ultimately dictate seniors' mobility 3Researchers Discover Gene That Determines Asthma Susceptibility By Regulating Inflammation 2Israeli scientists successfully transplant frozen-thawed ovaries in sheep 2Israeli scientists successfully transplant frozen-thawed ovaries in sheep 3
... I (RNase-free) (E.C. 3.1.21.1) is a nonspecific ... chromatin. It functions by hydrolyzing phosphodiester linkages, ... and a 3'-hydroxyl group. Ambion's RNase-free DNase ... and is recommended to degrade DNA in ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing ... want your precious antibody. This can cause ... • Receive royalties for your hard ... and let us build it up and ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: